# US 2010/0168022 A1 · Use of In-Vitro Culture to Design or Test Personalized Treatment Regimens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168022 A1
- Document ID: US20100168022A1
- Status: Published application
- Kind: A1
- Application number: 12/636,214
- Filed: 2009-12-11
- Published: 2010-07-01
- Earliest claimed: 2008-12-11
- Inventors: Christopher J. Centeno
- Web page: https://patentgrep.com/patent/US20100168022A1

## CPC

- G01N 33/5073: {Stem cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G16C 20/30: Prediction of properties of chemical compounds, compositions or mixtures
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 20/60: relating to nutrition control, e.g. diets
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Provided herein are methods of assessing responsiveness to an agent, methods of customizing treatments, methods of screening agents, and methods of treatment. Also provided are systems and kits for carrying out the methods contemplated herein. An exemplary aspect includes a method of assessing whether a subject having a condition, disorder, dysfunction, or disease would respond to treatment with an agent. The method comprises obtaining a stem cell sample from the subject; culturing the sample; exposing the sample to an agent; evaluating the sample in the presence of and in the absence of the agent to create a sample profile; and comparing the sample profile to a reference profile indicative of responsiveness to the agent. The similarity between the sample profile and the reference profile indicates the subject's responsiveness to the agent.

## Claims

### Claim 1

A method of assessing whether a subject having a condition, disorder, dysfunction, or disease would respond to treatment with an agent, the method comprising:
obtaining a stem cell sample from the subject;
culturing the sample;
exposing the sample to an agent;
evaluating the sample in the presence of and in the absence of the agent to create a sample profile;
comparing the sample profile to a reference profile indicative of responsiveness to the agent;
wherein the similarity between the sample profile and the reference profile indicates the subject's responsiveness to the agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the stem cell sample comprises embryonic stem cells, fetal stem cells, umbilical cord stem cells, placental derived stem cells, very small embryonic-like stem cells, or adult stem cells of hematopoietic, mesenchymal, epidermal, or endodermal lineages.

### Claim 3 (depends on 1)

The method of claim 1, wherein the agent is selected from the group consisting of nutritional supplements, nutraceuticals, growth factors, cytokines, hormones, essential nutrients, registered chemicals, novel chemicals, biologicals, and environmental reagents.

### Claim 4 (depends on 1)

The method of claim 1, wherein the step of evaluating comprises measuring a cellular response.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cellular response is selected from the group consisting of transcription, expression, protein activation, protein inactivation, proliferation, differentiation, apoptosis, and alteration in morphology.

### Claim 6 (depends on 5)

The method of claim 5, wherein the step of evaluating comprises measuring transcription using a microarray.

### Claim 7 (depends on 1)

The method of claim 1, wherein the reference profile is generated by evaluating one or more samples in the presence of and absence of one or more agents typically used to treat the condition, disorder, dysfunction, or disease.

### Claim 8 (depends on 7)

The method of claim 7, wherein the condition, disorder, dysfunction, or disease is selected from the group consisting of:
a) the degenerative conditions of aging selected from the group consisting of osteoarthritis, coronary heart disease, and osteoporosis;
b) disorders of the immune system selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, ankylosing spondylitis, scleroderma, and rheumatoid arthritis;
c) disorders of the neurologic system selected from the group consisting of Alzheimer's disease, Parkinson's, and spinal cord injury;
d) disorders of gastrointestinal system selected from the group consisting of irritable bowel syndrome, gastroesophageal reflux disease, Crohn's disease, and ulcerative colitis; and
e) disorders of the musculo skeletal system selected from the group consisting of cartilage injuries, tendonopathies, fibromyalgia, ligament injuries, degenerative disc disease, and sciatica.

### Claim 9

A method of providing a custom treatment for a subject, the method comprising:
obtaining a stem cell sample from the subject;
culturing the sample;
exposing the sample to an agent;
evaluating the sample in the presence of and in the absence of the agent to create a first sample profile;
comparing the first sample profile to a first reference profile indicative of non-responsiveness to the agent, wherein the similarity between the first sample profile and the first reference profile indicates the subject's non-responsiveness to the agent;
designing a custom compound and exposing the sample to the custom compound;
evaluating the sample in the presence of and in the absence of the custom compound to create a second sample profile;
comparing the second sample profile to a second reference profile indicative of responsiveness to the agent;
wherein the similarity between the second sample profile and the second reference profile indicates the subject's responsiveness to the custom compound; and
wherein the custom compound is provided to the subject as a custom treatment.

### Claim 10 (depends on 9)

The method of claim 9, wherein the custom compound comprises nutritional supplements, nutraceuticals, growth factors, cytokines, hormones, essential nutrients, registered chemicals, novel chemicals, biologicals, and environmental reagents.

### Claim 11 (depends on 9)

The method of claim 9, wherein the subject has altered chondrogenesis, osteogenesis, altered neurologic function or altered fibrogenesis.

### Claim 12

A method of screening a custom compound for efficacy, safety, or lack of adverse effect, the method comprising:
obtaining a stem cell sample from a subject;
culturing the sample;
exposing the sample to a custom compound;
evaluating the sample in the presence of and in the absence of the custom compound to create a sample profile;
comparing the sample profile to a reference profile generated by an agent which exhibits efficacy, safety, or lack of adverse effect;
wherein the similarity between the sample profile and the reference profile indicates the efficacy, safety, or lack of adverse effect of the custom compound.

### Claim 13 (depends on 12)

The method of claim 12, wherein the method further comprises the step of comparing the sample profile to a second reference profile generated by a second agent which exhibits an adverse effect.

### Claim 14 (depends on 12)

The method of claim 12, wherein the method further comprises the step of comparing the sample profile to a second reference profile generated by a second agent which exhibits undesired efficacy.

### Claim 15 (depends on 12)

The method of claim 12, wherein the method further comprises the step of comparing the sample profile to a second reference profile generated by a second agent which is unsafe.

### Claim 16

A method of treating a subject in need thereof, the method comprising:
obtaining a stem cell sample from the subject;
culturing the sample;
exposing the sample to an agent;
evaluating the sample in the presence of and in the absence of the agent to create a first sample profile;
comparing the first sample profile to a first reference profile indicative of non-responsiveness to the agent, wherein the similarity between the first sample profile and the first reference profile indicates the subject's non-responsiveness to the agent;
designing a custom compound and exposing the sample to the custom compound;
evaluating the sample in the presence of and in the absence of the custom compound to create a second sample profile;
comparing the second sample profile to a second reference profile indicative of responsiveness to the agent;
wherein the similarity between the second sample profile and the second reference profile indicates the subject's responsiveness to the custom compound; and
wherein the custom compound is provided to the subject as a custom treatment.

### Claim 17

A method of treating a subject in need thereof, the method comprising:
obtaining a stem cell sample from the subject;
culturing the sample;
exposing the sample to an agent;
evaluating the sample in the presence of and in the absence of the agent to create a sample profile;
comparing the sample profile to a reference profile indicative of responsiveness to the agent; wherein the similarity between the sample profile and the reference profile indicates the subject's responsiveness to the agent; and
treating the subject with the agent.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject suffers from:
a) degenerative conditions of aging selected from the group consisting of osteoarthritis, coronary heart disease, and osteoporosis;
b) disorders of the immune system selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, ankylosing spondylitis, scleroderma, and rheumatoid arthritis;
c) disorders of the neurologic system selected from the group consisting of Alzheimer's disease, Parkinson's, and spinal cord injury;
d) disorders of gastrointestinal system selected from the group consisting of irritable bowel syndrome, gastroesophageal reflux disease, Crohn's disease, and ulcerative colitis; and
e) disorders of the musculo skeletal system selected from the group consisting of cartilage injuries, tendonopathies, fibromyalgia, ligament injuries, degenerative disc disease, and sciatica.

### Claim 19 (depends on 17)

The method of claim 17, wherein the reference profile is generated by evaluating one or more samples in the presence of and absence of one or more agents used to treat:
a) degenerative conditions of aging selected from the group consisting of osteoarthritis, coronary heart disease, and osteoporosis;
b) disorders of the immune system selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, ankylosing spondylitis, scleroderma, and rheumatoid arthritis;
c) disorders of the neurologic system selected from the group consisting of Alzheimer's disease, Parkinson's, and spinal cord injury;
d) disorders of gastrointestinal system selected from the group consisting of irritable bowel syndrome, gastroesophageal reflux disease, Crohn's disease, and ulcerative colitis; and
e) disorders of the musculo skeletal system selected from the group consisting of cartilage injuries, tendonopathies, fibromyalgia, ligament injuries, degenerative disc disease, and sciatica.

### Claim 20

A computer-aided system comprising:
(a) a computer readable medium comprising computer-executable instructions configured to predict responsiveness of a subject to treatment with an agent;
(b) input data from: (i) a subject profile; and (ii) a reference profile; and
(c) an algorithm capable of comparing the data; wherein the system outputs a predicted responsiveness by the subject to the agent.

### Claim 21 (depends on 9)

The method of claim 9, wherein the custom compound is provided to the patient formulated as a cosmetic.

### Claim 22 (depends on 17)

The method of claim 17, wherein the agent is provided to the patient formulated as a cosmetic.
